<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04394286</url>
  </required_header>
  <id_info>
    <org_study_id>SHP648-101</org_study_id>
    <secondary_id>2018-004024-11</secondary_id>
    <nct_id>NCT04394286</nct_id>
  </id_info>
  <brief_title>A Phase 1/2 Study of SHP648, an Adeno-Associated Viral Vector for Gene Transfer in Hemophilia B Subjects</brief_title>
  <official_title>An Open-Label, Multinational, Phase 1/2 Study of the Safety and Dose Escalation of SHP648, an Adeno-Associated Virus Serotype 8 (AAV8) Vector Expressing FIX Padua in Hemophilia B Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baxalta now part of Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and dose escalation of SHP648 an
      adeno-associated viral vector for gene transfer in hemophilia B participants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will consists of 3 dose cohorts with 2-7 participants in each of the three
      ascending dose cohorts. Initially 2 participants will be dosed in Cohort 1, followed by
      dosing of up to 5 additional participants if the cohort is expanded. Participants in cohort 2
      and 3 will receive 2-fold or 3-fold dose escalation to their respective preceding cohort
      doses if required.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 13, 2020</start_date>
  <completion_date type="Anticipated">March 16, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 16, 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With SHP648 Related Serious or Non-Serious Adverse Events (AEs)</measure>
    <time_frame>From study drug administration to study completion/early termination (up to 12 months)</time_frame>
    <description>An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this investigational product (IP) or medicinal product. A Serious adverse event (SAE) was an AE resulting in any of the following outcomes: death; Life-threatening event; required or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly. AEs include both serious and Non-serious adverse events. Number of participants with incidence and severity of AEs will be assessed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma FIX levels before and after SHP648 infusion</measure>
    <time_frame>From study drug administration to study completion/early termination (up to 12 months)</time_frame>
    <description>Circulating plasma FIX activity and antigen levels before and after SHP648 administration will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized Bleed Rate (ABR)</measure>
    <time_frame>From study drug administration to study completion/early termination (up to 12 months)</time_frame>
    <description>ABR will be assessed based upon each individual bleeding episode. A bleed episode is defined as subjective (e.g., pain consistent with a joint bleed) or objective evidence of bleeding which may or may not require treatment with FIX. Annualized bleed rate (ABR) before and after SHP648 administration will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Positive Binding Antibody Titers to Adeno-Associated Virus (AAV8)</measure>
    <time_frame>Up to study completion/early termination (up to 12 months)</time_frame>
    <description>Number of participants with positive binding antibodies to AAV8 will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Positive Neutralizing Antibody Titers to Adeno-Associated Virus (AAV8)</measure>
    <time_frame>Up to study completion/early termination (up to 12 months)</time_frame>
    <description>Number of participants with positive neutralizing antibodies to AAV8 will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with T-cell Response to Adeno-Associated Virus (AAV8)</measure>
    <time_frame>Up to study completion/early termination (up to 12 months)</time_frame>
    <description>Number of participants with T-cell response to AAV8 will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with T-cell Response to Factor IX (FIX) Transgene Products</measure>
    <time_frame>Up to study completion/early termination (up to 12 months)</time_frame>
    <description>Number of participants with T-cell response to FIX transgene products will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of SHP648 Genomes Present in Bodily Fluids</measure>
    <time_frame>Up to study completion/early termination (up to 12 months)</time_frame>
    <description>Duration of SHP648 genomes present in bodily fluids such as serum, blood, saliva, urine, stool, and semen will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Consumption of Exogenous Factor IX (FIX) Before and After Gene Transfer</measure>
    <time_frame>Up to study completion/early termination (up to 12 months)</time_frame>
    <description>Percent change in consumption of exogenous FIX before and after gene transfer will be reported.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Hemophilia B</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1 participants will receive a single intravenous (IV) infusion of SHP648 on the day of dosing (Day 0).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 2 participants will receive a single IV infusion of SHP648 at a 2 to 3-fold escalation of Cohort 1 on the day of dosing (Day 0).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 3 participants will receive a single IV infusion of SHP648 at a 2 to 3-fold escalation of Cohort 2 on the day of dosing (Day 0).</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>SHP648</intervention_name>
    <description>Participants will receive a single IV infusion of SHP648 in Cohort 1, 2, 3 on Day 0.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <other_name>TAK748</other_name>
    <other_name>AAV8.ss-3xCRM8-TTR-FIX_R338Lopt</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male, aged 18 to 75 years at the time of screening.

          -  Established severe or moderately severe hemophilia B (plasma FIX activity lesser than
             or equal to [&lt;=] 2 percent (%) measured following greater than or equal to [&gt;=] 5
             half-lives of most recent exposure to exogenous FIX) and either &gt;= 3 hemorrhages per
             year requiring treatment with exogenous FIX or use of prophylactic therapy.

          -  History of greater than (&gt;) 50 exposure days to exogenously administered FIX
             concentrates or cryoprecipitates.

          -  Sexually active men must agree to use barrier contraception (combination of a condom
             and spermicide) or limit sexual intercourse to post-menopausal, surgically sterilized,
             or contraception-practicing partners for a minimum of 6 months after administration of
             SHP648, or until SHP648 genomes are no longer detected in the semen (whichever is
             sooner).

          -  Signed informed consent.

        Exclusion Criteria:

          -  Bleeding disorder(s) other than hemophilia B.

          -  Documented laboratory evidence of having developed inhibitors (&gt;= 0.6 Bethesda Units
             [BU] on any single test) to FIX proteins at any time.

          -  Documented prior allergic reaction to any FIX product.

          -  Anti-AAV8 neutralizing antibody titer &gt;= 1:5.

          -  Known hypersensitivity to prednisolone or prednisone, or to any of the excipients.

          -  Having a disease in which treatment with prednisolone or prednisone is not tolerated
             (including, but not limited to osteoporosis with vertebral fractures, severe labile
             hypertension, and brittle diabetes).

          -  Evidence of markers of potential underlying risk for autoimmune mediated hepatic
             disease:

               -  Anti-smooth muscle antibody (ASMA) titer &gt;= 1:40. Values of 1:31 to 1:39 will be
                  flagged as possibly abnormal and the Investigator and Medical Monitor will
                  evaluate the participant for eligibility

               -  Elevated anti-liver-kidney microsomal antibody type 1 (LKM1) titers

               -  Total Immunoglobulin G (IgG) &gt; 1.5x upper limit of normal (ULN)

               -  Antinuclear antibody (ANA) titer &gt; 1:320 OR ANA titer &gt; 1:80 if demonstrated
                  concurrently with alanine aminotransferase (ALT) that is &gt; ULN

          -  Active Hepatitis C: as indicated by detectable hepatitis C virus ribonucleic acid (HCV
             RNA) by polymerase chain reaction (PCR).

          -  Hepatitis B: If surface hepatitis B virus (HBV) antigen is positive.

          -  Receiving chronic systemic antiviral and/or interferon therapy within 4 weeks prior to
             enrollment.

          -  Clinically significant infections (e.g., systemic fungal infections) requiring
             systemic treatment.

          -  Known immune disorder (including myeloma and lymphoma).

          -  Concurrent chemotherapy or biological therapy for treatment of neoplastic disease or
             other disorders.

          -  An absolute neutrophil count lesser than &lt; 1000 cells per cubic millimetre
             (cells/mm^3).

          -  Markers of hepatic inflammation or cirrhosis as evidenced by 1 or more of the
             following:

               -  Platelet count &lt; 150,000/microliter (μL)

               -  Albumin &lt;= 3.5 gram per deciliter (g/dL)

               -  Total bilirubin &gt; 1.5x ULN and direct bilirubin &gt;= 0.5 milligram per deciliter
                  (mg/dL)

               -  ALT or Aspartate aminotransferase (AST) &gt; 1.0x ULN

               -  Alkaline phosphatase &gt; 2.0x ULN

               -  History of liver biopsy or imaging indicating moderate or severe fibrosis
                  (Metavir staging of F2 or greater)

               -  History of ascites, varices, variceal hemorrhage, or hepatic encephalopathy

               -  FibroSURE Score &gt;= 0.4

               -  Prothrombin time international normalized ratio (INR) &gt;= 1.4

          -  Serum creatinine &gt; 1.5 mg/dL.

          -  Human immunodeficiency virus (HIV) if cluster of differentiation 4 (CD4)+ cell count
             &lt;= 200 mm^3 and/or viral load &gt; 20 copies per milliliter (copies/mL).

          -  Urine protein &gt; 30 mg/dL.

          -  Body mass index &gt; 38.

          -  Orthopedic or other major surgery planned within 6 months after enrollment.

          -  Acute or chronic disease that, in the opinion of the Investigator, would adversely
             affect participant safety or compliance or interpretation of study results.

          -  Received an AAV vector previously or any other gene transfer agent in the previous 12
             months prior to Study Day 0.

          -  Significant cardiovascular disease (such as New York Heart Association Class III or IV
             cardiac disease, congestive heart failure, myocardial infarction within the previous 6
             months, unstable arrhythmias, or unstable angina) or significant pulmonary disease
             (including obstructive pulmonary disease).

          -  History of arterial or venous thrombosis / thromboembolism, or a known pro-thrombotic
             condition.

          -  Recent history of psychiatric illness or cognitive dysfunction (including drug or
             alcohol abuse) that, in the opinion of the Investigator, is likely to impair
             participants ability to comply with protocol mandated procedures.

          -  Participation in another study involved with an investigational agent.

          -  Participant is family member or employee of the Investigator.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Shire</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shire Contact</last_name>
    <phone>+1 866 842 5335</phone>
    <email>ClinicalTransparency@shire.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>AKH - Medizinische Universität Wien</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+43-1-40400-44480</phone>
      <email>ingrid.pabinger@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Ingrid Pabinger-Fasching</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Morvan</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+33298223650</phone>
      <email>brigitte.pan-petesch@chu-brest.fr</email>
    </contact>
    <investigator>
      <last_name>Brigitte Pan-Petesch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Groupement Hospitalier Sud - Hôpital Bicêtre</name>
      <address>
        <city>Le Kremlin Bicêtre</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+33 1 45212197</phone>
      <email>roseline.doiron@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Roseline D'oiron</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Jeanne de Flande - CHI Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+33 3 20 44 48 45</phone>
      <email>sophie.susen@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Sofie Susen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+33491386776</phone>
      <email>herve.chambost@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>Herve Chambost</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes Site Hotel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+33240087468</phone>
      <email>marc.trossaert@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Marc Trossaert</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Necker - Enfants Malades</name>
      <address>
        <city>Paris</city>
        <zip>75743</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+33144495292</phone>
      <email>laurant.frenzel@nck.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Laurant Frenzel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum der Johann Wolfgang Goethe-Universität</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+49 69 6301-5051</phone>
      <email>wolfgang.miesbach@kgu.de</email>
    </contact>
    <investigator>
      <last_name>Wolfgang Miesbach</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+36 30 4746416</phone>
      <email>takacs.istvan@med.semmelweis-univ.hu</email>
    </contact>
    <investigator>
      <last_name>Istvan Takacs</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chaim Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <zip>5266202</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+972-3-5307341</phone>
      <email>gili.kenet@sheba.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Kenet Gili</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Presidio Ospedaliero di Castelfranco Veneto</name>
      <address>
        <city>Castelfranco Veneto</city>
        <zip>31033</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+39423732346</phone>
      <email>paolo.radossi@aulss2.veneto.it</email>
    </contact>
    <investigator>
      <last_name>Paolo Radossi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Emofilia Azienda Ospedaliera Universitaria Careggi</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contactt</last_name>
      <phone>+390555947587</phone>
      <email>castaman@aou-careggi.toscana.it</email>
    </contact>
    <investigator>
      <last_name>Giancarlo Castaman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano Centro Emofilia e Trombosi</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+390255035421</phone>
      <email>flora.peyvandi@unimi.it</email>
    </contact>
    <investigator>
      <last_name>Flora Peyvandi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>8035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34 932746100</phone>
      <email>mgironella@vhio.net</email>
    </contact>
    <investigator>
      <last_name>Mercedes Gironella Mesa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Arrixaca</name>
      <address>
        <city>El Palmar</city>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34 968 369 352</phone>
      <email>jmoraled@um.es</email>
    </contact>
    <investigator>
      <last_name>José Maria Moraleda Jimenez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34 913582211</phone>
      <email>talvarezroman@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Maria Teresa Alvarez Roman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ege University Medical Faculty</name>
      <address>
        <city>Izmir</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+905424328738</phone>
      <email>kaan.kavakli61@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ramazan Kavakli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>Turkey</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 15, 2020</study_first_submitted>
  <study_first_submitted_qc>May 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2020</study_first_posted>
  <last_update_submitted>June 10, 2020</last_update_submitted>
  <last_update_submitted_qc>June 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
    <mesh_term>Hemophilia B</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Shire provides access to the de-identified individual participant data for eligible studies to aid qualified researchers in addressing legitimate scientific objectives. These IPDs will be provided following approval of a data sharing request, and under the terms of a data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_access_criteria>IPD from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.shiretrials.com website. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://www.shiretrials.com/en/our-commitment-to-transparency/data-sharing-with-researchers</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

